

Prof. Dr. med. Stephan Stilgenbauer

1. General Information

Name, Academic Title: Stephan Stilgenbauer, Prof. Dr. med.
Date and Place of Birth: 27.11.1966; Kaiserslautern, Germany
Sex: Male
Office Address: Department of Internal Medicine III, Ulm University, Albert-Einstein-Allee 23, 89081 Ulm, Germany
Phone: +49-731-500-45521
Fax: +49-731-500-45525
E-Mail: stephan.stilgenbauer@uniklinik-ulm.de
Current Position: Deputy chairman (Leitender Oberarzt), Department of Internal Medicine III, Ulm University
Children: Two (2 and 5 years)
Paternity Leave: None

2. University Education

10.6.1994	Medical Licensing Examination
1987-1994	Medical School, Heidelberg University

3. Academic Degrees

20.10.2005	Associate Professor of Medicine (<i>ausserplanmässige Professur</i>)
8.10.2002	Postdoctoral Thesis (<i>Habilitation</i>), Internal Medicine, Ulm University, Mentor: Prof. Hartmut Döhner
28.12.1994	Doctoral Thesis (<i>Dr. med.</i>), Medicine, Heidelberg University, Advisor: Prof. Peter P. Nawroth

4. Professional Experience

Since 2003	Associate Professor and Attending Physician (<i>Oberarzt</i>) Department of Internal Medicine III, Ulm University
Since 1999	Group leader of the CLL research laboratory and central reference laboratory genetics of the GCLLSSG
2004	Boards in Hematology and Medical Oncology
2002	Boards in Internal Medicine
1999-2002	Fellowship in Internal Medicine, Hematology, Oncology, Rheumatology, Infectious Diseases; Department of Internal Medicine III, Ulm University (Director: Prof. Dr. H. Döhner)
1996-1998	Postdoctoral laboratory research fellow at the Department “Organization of complex genomes” of the Deutsche Krebsforschungszentrum, Heidelberg, Germany (Head: Prof. P. Lichter)
1994-1999	Residency in Internal Medicine, Hematology, Oncology, Rheumatology; Department of Internal Medicine V, Heidelberg University (Director: Prof. W. Hunstein, Prof. R. Haas, Prof. A. D. Ho)

5. Awards, Honors, Positions

2011	Speaker of the “Else Kröner Forschungskolleg Ulm”, funded by the Else Kröner Fresenius Stiftung
2010	Module Director, Module 4 (Advanced/Integrated Therapies) Master Online Advanced Oncology Program, Ulm University
2008	Walther und Christine Richtzenhain Award of the German Cancer Research Center, Heidelberg
2006	Merckle Research Award, Ulm University
2002	Artur Pappenheim Award, German Society of Hematology and Oncology

2001

Leukemia Research Award, Franziska Kolb Foundation, Ulm University

6. Publications and Patents

1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bübler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. **Lancet**. 2010;376(9747):1164-74.
2. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. **Nat Rev Cancer**. 2010;10(1):37-50.
3. Stilgenbauer S, Zenz T, Winkler D, Bübler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsén U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the GCLLSG. **J Clin Oncol**. 2009;27(24):3994-4001.
4. Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D, Winkler D, Durig J, van Oers MH, Mertens D, Döhner H, Stilgenbauer S. miR-34a as part of the chemotherapy resistance network in chronic lymphocytic leukemia. **Blood**. 2009;113:3801-3808.
5. Mertens D, Wolf S, Mund C, Kienle D, Ohl S, Schroeter P, Tschuch C, Lyko F, Döhner H, Stilgenbauer S, Lichter P. Allelic silencing at the tumor suppressor locus 13q14.3 suggests a novel oncogenic mechanism. **Proc Natl Acad Sci U S A**. 2006;103(20):7741-6.

Patent

"Superior efficacy of CD37 antibodies in CLL blood samples" US, European and International (PCT EU 2010/1633) patent applications filed